Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antiviral Agents | 7 | 2024 | 3070 | 0.650 |
Why?
|
HIV Infections | 25 | 2024 | 17591 | 0.640 |
Why?
|
Sarcoma, Kaposi | 3 | 2024 | 375 | 0.500 |
Why?
|
Anti-HIV Agents | 13 | 2024 | 4576 | 0.500 |
Why?
|
Disease Outbreaks | 3 | 2021 | 1761 | 0.430 |
Why?
|
RNA, Viral | 11 | 2024 | 2871 | 0.390 |
Why?
|
Viral Load | 6 | 2024 | 3398 | 0.320 |
Why?
|
Nucleosomes | 1 | 2012 | 492 | 0.300 |
Why?
|
Influenza, Human | 2 | 2016 | 1542 | 0.280 |
Why?
|
Lamivudine | 2 | 2018 | 367 | 0.280 |
Why?
|
Anti-Retroviral Agents | 3 | 2021 | 1795 | 0.260 |
Why?
|
Population Surveillance | 1 | 2016 | 2597 | 0.260 |
Why?
|
Antibodies, Viral | 7 | 2024 | 3215 | 0.250 |
Why?
|
Heterocyclic Compounds, 3-Ring | 2 | 2018 | 296 | 0.250 |
Why?
|
Cytomegalovirus Infections | 2 | 2023 | 839 | 0.240 |
Why?
|
Epitopes, B-Lymphocyte | 1 | 2024 | 85 | 0.230 |
Why?
|
Control Groups | 1 | 2023 | 107 | 0.210 |
Why?
|
Virus Shedding | 2 | 2023 | 110 | 0.200 |
Why?
|
Feedback, Physiological | 1 | 2024 | 481 | 0.200 |
Why?
|
Herpesvirus 8, Human | 1 | 2024 | 256 | 0.190 |
Why?
|
Influenza A Virus, H1N1 Subtype | 2 | 2016 | 453 | 0.190 |
Why?
|
Antibodies, Monoclonal | 8 | 2024 | 9264 | 0.190 |
Why?
|
AIDS-Related Opportunistic Infections | 2 | 2024 | 664 | 0.180 |
Why?
|
Biological Assay | 1 | 2023 | 628 | 0.180 |
Why?
|
Alkynes | 1 | 2021 | 327 | 0.180 |
Why?
|
Atrial Fibrillation | 6 | 2014 | 5176 | 0.170 |
Why?
|
South Africa | 2 | 2016 | 1872 | 0.170 |
Why?
|
Cyclopropanes | 1 | 2021 | 437 | 0.170 |
Why?
|
Chromatin | 1 | 2012 | 2981 | 0.170 |
Why?
|
Benzoxazines | 1 | 2021 | 321 | 0.170 |
Why?
|
Receptors, Urokinase Plasminogen Activator | 1 | 2019 | 76 | 0.170 |
Why?
|
Cytomegalovirus | 2 | 2023 | 753 | 0.160 |
Why?
|
Adult | 34 | 2024 | 223851 | 0.160 |
Why?
|
Nitriles | 2 | 2022 | 990 | 0.160 |
Why?
|
Pyrimidines | 2 | 2022 | 3048 | 0.160 |
Why?
|
Bleomycin | 1 | 2020 | 493 | 0.160 |
Why?
|
HIV | 6 | 2023 | 1597 | 0.160 |
Why?
|
Galectins | 1 | 2021 | 295 | 0.160 |
Why?
|
Humans | 61 | 2024 | 768970 | 0.160 |
Why?
|
Genitalia | 1 | 2018 | 114 | 0.150 |
Why?
|
DNA | 1 | 2012 | 7214 | 0.150 |
Why?
|
Body Composition | 2 | 2019 | 2462 | 0.150 |
Why?
|
Arginine | 1 | 2021 | 932 | 0.150 |
Why?
|
Osteoprotegerin | 1 | 2018 | 179 | 0.140 |
Why?
|
Vincristine | 1 | 2020 | 1040 | 0.140 |
Why?
|
DNA, Viral | 2 | 2023 | 2205 | 0.140 |
Why?
|
Models, Statistical | 1 | 2012 | 5110 | 0.140 |
Why?
|
Middle Aged | 28 | 2024 | 223737 | 0.130 |
Why?
|
RANK Ligand | 1 | 2018 | 321 | 0.130 |
Why?
|
Inflammation | 4 | 2023 | 10868 | 0.130 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2022 | 2203 | 0.130 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2020 | 682 | 0.130 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2020 | 622 | 0.130 |
Why?
|
Administration, Oral | 1 | 2024 | 4040 | 0.130 |
Why?
|
Hong Kong | 1 | 2015 | 170 | 0.120 |
Why?
|
Bone Density | 2 | 2020 | 3574 | 0.120 |
Why?
|
Male | 35 | 2024 | 365203 | 0.120 |
Why?
|
Death | 1 | 2019 | 683 | 0.120 |
Why?
|
Herpesvirus 4, Human | 1 | 2020 | 1082 | 0.120 |
Why?
|
Singapore | 1 | 2015 | 299 | 0.110 |
Why?
|
Pyrazoles | 2 | 2022 | 2029 | 0.110 |
Why?
|
Abdominal Fat | 1 | 2016 | 221 | 0.110 |
Why?
|
Severe Acute Respiratory Syndrome | 1 | 2015 | 136 | 0.110 |
Why?
|
Female | 35 | 2024 | 397515 | 0.110 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2020 | 617 | 0.110 |
Why?
|
Antiretroviral Therapy, Highly Active | 5 | 2021 | 1903 | 0.110 |
Why?
|
Antibodies, Neutralizing | 4 | 2024 | 2009 | 0.110 |
Why?
|
Lipoproteins, LDL | 1 | 2016 | 643 | 0.110 |
Why?
|
Waist Circumference | 1 | 2017 | 935 | 0.110 |
Why?
|
Contact Tracing | 1 | 2015 | 275 | 0.100 |
Why?
|
HIV-1 | 3 | 2018 | 6962 | 0.100 |
Why?
|
Vaccination | 1 | 2024 | 3438 | 0.100 |
Why?
|
Japan | 1 | 2016 | 1418 | 0.100 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2024 | 4413 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2023 | 10400 | 0.100 |
Why?
|
Lipoproteins, HDL | 1 | 2016 | 682 | 0.100 |
Why?
|
Intra-Abdominal Fat | 1 | 2017 | 625 | 0.100 |
Why?
|
Outpatients | 3 | 2024 | 1603 | 0.090 |
Why?
|
Disease Transmission, Infectious | 1 | 2016 | 560 | 0.090 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2024 | 4651 | 0.090 |
Why?
|
Genome, Fungal | 1 | 2012 | 203 | 0.090 |
Why?
|
C-Reactive Protein | 3 | 2021 | 3859 | 0.090 |
Why?
|
Hospitalization | 3 | 2024 | 10847 | 0.090 |
Why?
|
Aged | 14 | 2024 | 171786 | 0.090 |
Why?
|
Gonadal Steroid Hormones | 1 | 2014 | 708 | 0.080 |
Why?
|
Confidence Intervals | 1 | 2015 | 2932 | 0.080 |
Why?
|
Risk Assessment | 4 | 2014 | 24333 | 0.080 |
Why?
|
T-Lymphocyte Subsets | 1 | 2016 | 1813 | 0.070 |
Why?
|
Markov Chains | 1 | 2012 | 979 | 0.070 |
Why?
|
Insulin Resistance | 1 | 2022 | 3982 | 0.070 |
Why?
|
Adipose Tissue | 1 | 2019 | 3335 | 0.070 |
Why?
|
Adiposity | 1 | 2017 | 1895 | 0.070 |
Why?
|
Subcutaneous Fat | 2 | 2021 | 404 | 0.070 |
Why?
|
Bayes Theorem | 1 | 2015 | 2360 | 0.070 |
Why?
|
Muscle, Skeletal | 1 | 2021 | 4978 | 0.070 |
Why?
|
Age Factors | 4 | 2016 | 18435 | 0.070 |
Why?
|
Drug Resistance, Viral | 2 | 2024 | 869 | 0.070 |
Why?
|
HIV Protease Inhibitors | 2 | 2021 | 432 | 0.070 |
Why?
|
Oxazines | 2 | 2018 | 358 | 0.070 |
Why?
|
Drug Therapy, Combination | 3 | 2024 | 6320 | 0.060 |
Why?
|
Kinetics | 2 | 2023 | 6332 | 0.060 |
Why?
|
Myocardial Infarction | 4 | 2021 | 11521 | 0.060 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2014 | 1751 | 0.060 |
Why?
|
Protease Inhibitors | 2 | 2020 | 752 | 0.060 |
Why?
|
CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2024 | 46 | 0.060 |
Why?
|
Ritonavir | 2 | 2016 | 332 | 0.060 |
Why?
|
ROC Curve | 1 | 2012 | 3629 | 0.060 |
Why?
|
Menopause | 1 | 2012 | 1656 | 0.060 |
Why?
|
Hypoalbuminemia | 1 | 2024 | 90 | 0.060 |
Why?
|
Pandemics | 1 | 2023 | 8749 | 0.050 |
Why?
|
Young Adult | 6 | 2024 | 60131 | 0.050 |
Why?
|
WT1 Proteins | 1 | 2024 | 184 | 0.050 |
Why?
|
Pyridones | 2 | 2018 | 819 | 0.050 |
Why?
|
Half-Life | 1 | 2023 | 651 | 0.050 |
Why?
|
Peptide Fragments | 1 | 2014 | 5151 | 0.050 |
Why?
|
Aged, 80 and over | 5 | 2024 | 59739 | 0.050 |
Why?
|
Computer Simulation | 1 | 2015 | 6291 | 0.050 |
Why?
|
Basic Reproduction Number | 1 | 2021 | 38 | 0.050 |
Why?
|
Prospective Studies | 7 | 2021 | 54962 | 0.050 |
Why?
|
Metabolic Clearance Rate | 1 | 2021 | 363 | 0.050 |
Why?
|
Saccharomyces cerevisiae | 1 | 2012 | 2682 | 0.050 |
Why?
|
Heart Failure | 3 | 2013 | 11879 | 0.040 |
Why?
|
Janus Kinases | 1 | 2021 | 253 | 0.040 |
Why?
|
Adipokines | 1 | 2022 | 309 | 0.040 |
Why?
|
Subcutaneous Fat, Abdominal | 1 | 2019 | 91 | 0.040 |
Why?
|
Protein Isoforms | 1 | 2024 | 1714 | 0.040 |
Why?
|
Double-Blind Method | 2 | 2023 | 12467 | 0.040 |
Why?
|
Weight Gain | 2 | 2022 | 2359 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2019 | 20776 | 0.040 |
Why?
|
HIV-Associated Lipodystrophy Syndrome | 1 | 2019 | 138 | 0.040 |
Why?
|
Etoposide | 1 | 2020 | 639 | 0.040 |
Why?
|
Drug Combinations | 1 | 2024 | 2089 | 0.040 |
Why?
|
Body Fat Distribution | 1 | 2019 | 246 | 0.040 |
Why?
|
Incidence | 5 | 2014 | 21547 | 0.040 |
Why?
|
Immunocompromised Host | 1 | 2023 | 863 | 0.040 |
Why?
|
Piperazines | 2 | 2018 | 2553 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2023 | 1737 | 0.040 |
Why?
|
Africa | 1 | 2020 | 726 | 0.040 |
Why?
|
Treatment Outcome | 5 | 2024 | 65480 | 0.040 |
Why?
|
Drug Interactions | 1 | 2021 | 1418 | 0.030 |
Why?
|
Stroke | 2 | 2021 | 9756 | 0.030 |
Why?
|
Immune System | 1 | 2021 | 800 | 0.030 |
Why?
|
Morbidity | 1 | 2021 | 1757 | 0.030 |
Why?
|
Phosphoproteins | 1 | 2024 | 2452 | 0.030 |
Why?
|
Tandem Mass Spectrometry | 1 | 2021 | 1197 | 0.030 |
Why?
|
Aging | 1 | 2014 | 8745 | 0.030 |
Why?
|
Algorithms | 2 | 2013 | 14201 | 0.030 |
Why?
|
Infant | 1 | 2016 | 36556 | 0.030 |
Why?
|
Absorptiometry, Photon | 1 | 2020 | 1758 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2013 | 12562 | 0.030 |
Why?
|
Child, Preschool | 1 | 2016 | 42683 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2012 | 20245 | 0.030 |
Why?
|
Radioimmunoassay | 1 | 2014 | 862 | 0.030 |
Why?
|
Bacterial Infections | 1 | 2021 | 1397 | 0.030 |
Why?
|
Adolescent | 2 | 2024 | 89244 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2020 | 1855 | 0.030 |
Why?
|
HIV Integrase Inhibitors | 1 | 2015 | 165 | 0.030 |
Why?
|
Heart Murmurs | 1 | 2013 | 92 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2021 | 22296 | 0.030 |
Why?
|
RNA | 1 | 2023 | 2727 | 0.030 |
Why?
|
Iceland | 1 | 2013 | 183 | 0.030 |
Why?
|
Paclitaxel | 1 | 2020 | 1735 | 0.030 |
Why?
|
Risk Factors | 5 | 2024 | 74976 | 0.030 |
Why?
|
Ambulatory Care | 1 | 2023 | 2784 | 0.020 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2015 | 622 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2021 | 3232 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2016 | 1866 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2023 | 4568 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2024 | 3592 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2019 | 14794 | 0.020 |
Why?
|
Body Weight | 1 | 2021 | 4628 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3952 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15471 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2016 | 2226 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4862 | 0.020 |
Why?
|
Recurrence | 1 | 2022 | 8513 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2017 | 6236 | 0.020 |
Why?
|
Child | 1 | 2016 | 80960 | 0.020 |
Why?
|
Age Distribution | 1 | 2014 | 2875 | 0.020 |
Why?
|
Netherlands | 1 | 2013 | 2277 | 0.020 |
Why?
|
Time Factors | 2 | 2023 | 40261 | 0.020 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2013 | 856 | 0.020 |
Why?
|
Biopsy | 1 | 2019 | 6805 | 0.020 |
Why?
|
Europe | 1 | 2014 | 3441 | 0.020 |
Why?
|
Developing Countries | 1 | 2020 | 2911 | 0.020 |
Why?
|
Body Mass Index | 2 | 2017 | 13055 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2023 | 81903 | 0.020 |
Why?
|
Software | 1 | 2021 | 4479 | 0.020 |
Why?
|
Survival Analysis | 1 | 2019 | 10115 | 0.020 |
Why?
|
Linear Models | 1 | 2016 | 5891 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 26395 | 0.020 |
Why?
|
Antigens, CD | 1 | 2016 | 4032 | 0.020 |
Why?
|
Cohort Studies | 3 | 2013 | 41808 | 0.020 |
Why?
|
Self Report | 1 | 2017 | 3773 | 0.020 |
Why?
|
Pilot Projects | 1 | 2018 | 8748 | 0.010 |
Why?
|
Diabetes Mellitus | 2 | 2013 | 5892 | 0.010 |
Why?
|
Prevalence | 1 | 2021 | 15879 | 0.010 |
Why?
|
Prognosis | 2 | 2014 | 30046 | 0.010 |
Why?
|
Overweight | 1 | 2013 | 2448 | 0.010 |
Why?
|
United States | 3 | 2014 | 73186 | 0.010 |
Why?
|
Survival Rate | 1 | 2014 | 12873 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2013 | 12095 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11886 | 0.010 |
Why?
|
Mutation | 1 | 2022 | 30266 | 0.010 |
Why?
|
Smoking | 1 | 2013 | 9094 | 0.010 |
Why?
|
Hypertension | 1 | 2013 | 8617 | 0.010 |
Why?
|
Neoplasms | 1 | 2021 | 22389 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2014 | 39394 | 0.010 |
Why?
|
Concepts
(208)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(19)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_